In HPV-unrelated, cisplatin-resistant, ERB-resistant, recurrent, and metastatic head and neck squamous cell carcinoma (HNSCC), combination therapy of PAL and ERB demonstrated some promising results in a phase II clinical trial [51]. The gene discussed is ESR2; the disease is head and neck squamous cell carcinoma.